

## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings of claims, in the specification.

### **Listing of Claims:**

1. (original) A method for inhibiting EGF receptor signalling, said method comprising contacting a cell having EGF receptors and Frizzled (Fz) at the cell surface with a Wnt antagonist in a sufficient amount to reduce the EGF receptor signalling in said cell.
2. (original) The method of claim 1, wherein said EGF receptor is ErbB1.
3. (currently amended) The method of claim 1 ~~or 2~~, wherein said Wnt antagonist is an antagonist of Wnt1 or Wnt5a.
4. (currently amended) The method of ~~any one of the preceding claims~~, wherein the antagonist is an; antibody or fragment thereof, which specifically binds to Wnt.
5. (currently amended) The method of ~~any one of claims 1 to 3~~, wherein the antagonoist is an antibody or fragment thereof, which specifically binds to Fz.
6. (currently amended) The method of ~~any one of claims 1 to 3~~, wherein the antagonist is sFRP.
7. (currently amended) The method of as claimed in ~~any one of the preceding claims~~ wherein said cell is an epithelial cell.
8. (currently amended) The method of as claimed in ~~any one of the preceding claims~~, wherein said cell is a solid tumor cell.
9. (original) The method of claim 8, wherein said tumor cell is a breast cancer cell.
10. (original) The use of a Wnt antagonist to inhibit EGF receptor signalling.
11. (original) A method of screening for compounds effective in modulating Wnt-mediated ErbB receptor signalling, said method comprising:
  - (a) contacting a Wnt receptor (Fz) with Wnt in the presence of a candidate compound,
  - (b) detecting binding of Wnt or said candidate compound to said Wnt receptor and

- (c) correlating the binding of said candidate compound to said Wnt receptor or a change in binding of Wnt to said Wnt receptor relative to when said candidate compound is absent with a potential ErbB modulator.
- 12. (original) The method of claim 11, wherein said method is cell based.
- 13. (original) The method of claim 12, further comprising detecting ErbB signalling.
- 14. (original) The method of claim 13, wherein said ErbB signalling is detected by the presence of ERK activity, MARK activity, ErbB phosphotyrosine or cyclin D.
- 15. (original) The method of claim 13, wherein said ErbB signalling is detected by the presence of a reporter gene product.
- 16. (currently amended) The method of ~~any one of claims 13 to 15~~, wherein said candidate compound inhibits ErbB signalling.
- 17. (original) A kit comprising:
  - (a) a Wnt, a Fz, and/or a cell expressing Wnt and/or Fz; and
  - (b) a means of detecting ErbB signalling.
- 18. (original) The kit of claim 17, wherein said means of detecting ErbB signalling is an antibody.
- 19. (original) The kit of claim as claim 18, wherein the antibody comprises a detectable tag or label.
- 20. (original) A method for inhibiting ErbB signalling in a patient, comprising administering to the patient a composition comprising a Wnt antagonist in a sufficient amount to reduce the ErbB signalling in a cell of the patient.
- 21. (original) The method of claim 20, wherein the antagonist is an antibody or a fragment thereof that specifically binds to Wnt.
- 22. (original) The method of claim 20, wherein the antagonoist is an antibody or fragment thereof that specifically binds to Fz.
- 23. (currently amended) The method of ~~any one of claims 20-22~~, wherein the disorder is cancer.
- 24. (original) The method of claim 23, wherein said cancer is breast or colon cancer.
- 25. (original) The method of claim 24, wherein said cancer expresses ErbB1.

26. (original) Use of a Wnt antagonist for the manufacture of a medicament for the treatment of ErbB expressing cancers.
27. (original) A method of diagnosing a patient in need of treatment with a Wnt antagonist, said method comprising detecting ErbB receptor signalling.